John P. Hamill

CIK: 0001716213

Transaction Breakdown

Open Market Buys (P)6 (75.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

APRE

Aprea Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

APRE
Aprea Therapeutics, Inc.
Mar 31, 2026
Purchase(P)
Common Warrant
Direct
31K shares-
APRE
Aprea Therapeutics, Inc.
Mar 31, 2026
Purchase(P)
Pre-Funded Warrant
Direct
31K shares at avg. $0.81-
APRE
Aprea Therapeutics, Inc.
Mar 12, 2026
Award(A)
Direct
10.1K shares-
APRE
Aprea Therapeutics, Inc.
Jan 30, 2026
Purchase(P)
Direct
5.7K shares at avg. $0.89$5K
APRE
Aprea Therapeutics, Inc.
Dec 10, 2025
Purchase(P)
Direct
5K shares at avg. $1.17$6K
APRE
Aprea Therapeutics, Inc.
Mar 27, 2025
Award(A)
Direct
3.4K shares-
APRE
Aprea Therapeutics, Inc.
Oct 11, 2024
Purchase(P)
Direct
50 shares at avg. $2.46$123.19
APRE
Aprea Therapeutics, Inc.
Oct 10, 2024
Purchase(P)
Direct
450 shares at avg. $2.61$1K

		Type	Shares	Price		Ownership
Mar 31, 2026	APRE Aprea Therapeutics, Inc.	Purchase(P) Common Warrant	30,978	-	-	Direct
Mar 31, 2026	APRE Aprea Therapeutics, Inc.	Purchase(P) Pre-Funded Warrant	30,978	$0.81	-	Direct
Mar 12, 2026	APRE Aprea Therapeutics, Inc.	Award(A)	10,095	-	$0	Direct
Jan 30, 2026	APRE Aprea Therapeutics, Inc.	Purchase(P)	5,700	$0.89	$5,073	Direct
Dec 10, 2025	APRE Aprea Therapeutics, Inc.	Purchase(P)	5,000	$1.17	$5,825	Direct
Mar 27, 2025	APRE Aprea Therapeutics, Inc.	Award(A)	3,365	-	-	Direct
Oct 11, 2024	APRE Aprea Therapeutics, Inc.	Purchase(P)	50	$2.46	$123	Direct
Oct 10, 2024	APRE Aprea Therapeutics, Inc.	Purchase(P)	450	$2.61	$1,175	Direct

1-8 of 8 transactions

About Hamill John P.

Hamill John P. (SEC CIK 0001716213) files insider reports with the SEC as SrVP/CFO/Prin Fin & Acct Ofcr of Aprea Therapeutics, Inc. (APRE).

Signal8 holds 7 ownership filings by Hamill John P., all Form 4s, filed between Oct 15, 2024 and Apr 1, 2026. Those filings report 8 transactions, from Oct 10, 2024 to Mar 31, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Hamill John P.'s filings is in DOYLESTOWN, PA.

Recent filings by Hamill John P.

Mar 31, 2026: Open-market purchases of APRE derivative securities (2 lines, Form 4, code P).
Mar 12, 2026: Grant or award of APRE shares (Form 4, code A).
Jan 30, 2026: Open-market purchase of APRE shares (Form 4, code P).
Dec 10, 2025: Open-market purchase of APRE shares (Form 4, code P).
Mar 27, 2025: Grant or award of APRE shares (Form 4, code A).

Other insiders filing for Aprea Therapeutics, Inc. (APRE)

Grissinger Michael, Director
Gruia Gabriela, Director
Peters Richard, Director
HENNEMAN JOHN B III, Director
BIZZARI JEAN-PIERRE, Director
Duey Marc, Director

How to read Form 4 transaction codes